97 related articles for article (PubMed ID: 10544030)
1. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells.
Kouchi H; Nakamura K; Fushimi K; Sakaguchi M; Miyazaki M; Ohe T; Namba M
Biochem Biophys Res Commun; 1999 Nov; 264(3):915-20. PubMed ID: 10544030
[TBL] [Abstract][Full Text] [Related]
2. Manumycin inhibits cell proliferation and the Ras signal transduction pathway in human hepatocellular carcinoma cells.
Zhou JM; Zhu XF; Pan QC; Liao DF; Li ZM; Liu ZC
Int J Mol Med; 2003 Jun; 11(6):767-71. PubMed ID: 12736720
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway].
Zhou JM; Pan QC; Yang XP; Liu ZC; Liao DF; Fu LW; Liang YJ
Ai Zheng; 2002 Apr; 21(4):364-8. PubMed ID: 12452012
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of heat shock protein 70 in adherent ovarian cancer and mesothelioma following treatment with manumycin, a farnesyl transferase inhibitor.
Hu W; Wu W; Yeung SC; Freedman RS; Kavanagh JJ; Verschraegen CF
Anticancer Res; 2002; 22(2A):665-72. PubMed ID: 12014635
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin.
Kainuma O; Asano T; Hasegawa M; Kenmochi T; Nakagohri T; Tokoro Y; Isono K
Pancreas; 1997 Nov; 15(4):379-83. PubMed ID: 9361092
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice.
Sugita M; Sugita H; Kaneki M
Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1390-5. PubMed ID: 17363690
[TBL] [Abstract][Full Text] [Related]
7. Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells.
Di Paolo A; Danesi R; Nardini D; Bocci G; Innocenti F; Fogli S; Barachini S; Marchetti A; Bevilacqua G; Del Tacca M
Br J Cancer; 2000 Feb; 82(4):905-12. PubMed ID: 10732765
[TBL] [Abstract][Full Text] [Related]
8. Effects of the farnesyltransferase inhibitor UCF-1C/manumycin on growth and p21-ras post-translational processing in NIH3T3 cells.
Servais P; Gulbis B; Fokan D; Galand P
Int J Cancer; 1998 May; 76(4):601-8. PubMed ID: 9590140
[TBL] [Abstract][Full Text] [Related]
9. Akt-dependent antiapoptotic action of insulin is sensitive to farnesyltransferase inhibitor.
Park D; Pandey SK; Maksimova E; Kole S; Bernier M
Biochemistry; 2000 Oct; 39(41):12513-21. PubMed ID: 11027130
[TBL] [Abstract][Full Text] [Related]
10. Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Miyagawa J; Mitsui H; Yamamoto K; Kinoshita M; Matsuzawa Y
Br J Cancer; 1997; 76(8):1001-10. PubMed ID: 9376258
[TBL] [Abstract][Full Text] [Related]
11. Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells.
Frassanito MA; Cusmai A; Piccoli C; Dammacco F
Br J Haematol; 2002 Jul; 118(1):157-65. PubMed ID: 12100143
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of non-Ras protein farnesylation reduces in-stent restenosis.
Coats P; Kennedy S; Pyne S; Wainwright CL; Wadsworth RM
Atherosclerosis; 2008 Apr; 197(2):515-23. PubMed ID: 17662987
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of corneal inflammation by the topical use of Ras farnesyltransferase inhibitors: selective inhibition of macrophage localization.
Sonoda K; Sakamoto T; Yoshikawa H; Ashizuka S; Ohshima Y; Kishihara K; Nomoto K; Ishibashi T; Inomata H
Invest Ophthalmol Vis Sci; 1998 Nov; 39(12):2245-51. PubMed ID: 9804132
[TBL] [Abstract][Full Text] [Related]
14. Farnesyltransferase inhibitors reduce Ras activation and ameliorate acetaminophen-induced liver injury in mice.
Saha B; Nandi D
Hepatology; 2009 Nov; 50(5):1547-57. PubMed ID: 19739265
[TBL] [Abstract][Full Text] [Related]
15. [Growth inhibition of human pancreatic cancer by farnesyl transferase inhibitor].
Kainuma O; Asano T; Hasegawa M; Isono K
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1657-9. PubMed ID: 8886038
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells.
Di Paolo A; Danesi R; Caputo S; Macchia M; Lastella M; Boggi U; Mosca F; Marchetti A; Del Tacca M
Br J Cancer; 2001 Jun; 84(11):1535-43. PubMed ID: 11384105
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Nicholl SM; Roztocil E; Davies MG
J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
[TBL] [Abstract][Full Text] [Related]
18. Suppressive effect of RAS inhibitor manumycin A on aberrant crypt foci formation in the azoxymethane-induced rat colorectal carcinogenesis model.
Tsuda M; Okamoto K; Muguruma N; Sannomiya K; Nakagawa T; Miyamoto H; Kitamura S; Goji T; Kimura T; Okahisa T; Izumi K; Takayama T
J Gastroenterol Hepatol; 2013 Oct; 28(10):1616-23. PubMed ID: 23730936
[TBL] [Abstract][Full Text] [Related]
19. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells.
Liang KW; Yin SC; Ting CT; Lin SJ; Hsueh CM; Chen CY; Hsu SL
Eur J Pharmacol; 2008 Aug; 590(1-3):343-54. PubMed ID: 18590725
[TBL] [Abstract][Full Text] [Related]
20. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration.
Pukac L; Huangpu J; Karnovsky MJ
Exp Cell Res; 1998 Aug; 242(2):548-60. PubMed ID: 9683541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
